Liposomal amphotericin (L-AMB) is a widely used broad-spectrum anti-fungal drug. Although L-AMB demonstrates better safety compared with amphotericin, renal dysfunction and hypokalemia are well-known adverse effects of L-AMB.
We analyzed 56 episodes in 40 children and adolescents who received L-AMB therapy to determine risk factors of hypokalemia.
Hypokalemia (<3.0 mEq/L continuously for more than two episodes) was observed in 31 out of 56 episodes (55.4%). The median onset of hypokalemia was at 10 days on L-AMB (range, 3–54 days), and the median cumulative dose of L-AMB at occurrence of hypokalemia was 25 mg/kg (range, 10–167.5 mg/kg). None of the patients with hypokalemia had solid tumors, and they had significantly higher estimated glomerular filtration rates (eGFR) than those with normokalemia (p=0.013). Seven of 25 (28.0%) patients in the normokalemia group and 1 of 31 (3.2%) patients in the hypokalemia group had eGFRs of <90 mL/min/1.73 m2 (p=0.017).
Although the reason for the association between eGFR and hypokalemia is unclear, assessing the eGFR before L-AMB administration may predict the development of hypokalemia
Conflict of interest: All authors declare that there are no conflicts of interest to disclose.
All authors declare that there are no conflicts of interest to disclose.
Correspondence to: Ryoji Kobayashi, MD, Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishiku, Sapporo 003-0006, Japan. TEL: +81-11-865-0111, FAX: +81-11-865-9719, E-mail: email@example.com
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.